{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-normal&page=8", "query": { "condition": "HER2-normal", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 1186, "total_pages": 119, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-normal&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-normal&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-08T18:52:18.889Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05384119", "title": "Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "TTI-101", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Aromatase inhibitor (AI)", "type": "DRUG" }, { "name": "fulvestrant", "type": "DRUG" }, { "name": "ribociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tvardi Therapeutics, Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2023-01-09", "completion_date": "2024-05-06", "has_results": true, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-11-08T18:52:18.889Z", "location_count": 6, "location_summary": "Fort Lauderdale, Florida • St Louis, Missouri • Nashville, Tennessee + 2 more", "locations": [ { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05384119" }, { "nct_id": "NCT02040857", "title": "Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" }, { "name": "Aromatase Inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 162, "start_date": "2014-01", "completion_date": "2024-12-27", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-11-08T18:52:18.889Z", "location_count": 10, "location_summary": "San Francisco, California • Indianapolis, Indiana • Boston, Massachusetts + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02040857" }, { "nct_id": "NCT03734029", "title": "Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Trastuzumab deruxtecan (DS-8201a)", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 557, "start_date": "2018-12-27", "completion_date": "2026-05-19", "has_results": true, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-11-08T18:52:18.889Z", "location_count": 38, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Goodyear, Arizona + 31 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03734029" }, { "nct_id": "NCT01327781", "title": "Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2/Neu Positive", "Recurrent Breast Carcinoma", "Stage IIIC Breast Cancer AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Endoxifen Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 62, "start_date": "2011-03-25", "completion_date": "2026-10-30", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-11-08T18:52:18.889Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01327781" }, { "nct_id": "NCT01148849", "title": "Safety Study of MGAH22 in HER2-positive Carcinomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Gastric Cancer" ], "interventions": [ { "name": "margetuximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2010-07", "completion_date": "2022-06-14", "has_results": false, "last_update_posted_date": "2025-02-26", "last_synced_at": "2026-11-08T18:52:18.889Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Nashville, Tennessee", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01148849" }, { "nct_id": "NCT02340221", "title": "A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Taselisib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 631, "start_date": "2015-04-09", "completion_date": "2021-06-29", "has_results": true, "last_update_posted_date": "2022-07-12", "last_synced_at": "2026-11-08T18:52:18.889Z", "location_count": 16, "location_summary": "Tucson, Arizona • Atlanta, Georgia • Marietta, Georgia + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Harvey", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02340221" }, { "nct_id": "NCT01132664", "title": "Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Breast Cancer", "HER2+ Breast Cancer" ], "interventions": [ { "name": "BKM120", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2010-05", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2016-08-17", "last_synced_at": "2026-11-08T18:52:18.889Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Tampa, Florida + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Tampa", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01132664" }, { "nct_id": "NCT05029999", "title": "CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-negative Breast Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "PLD Chemotherapy", "type": "DRUG" }, { "name": "CDX-1140", "type": "DRUG" }, { "name": "CDX-301", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 30, "start_date": "2022-04-20", "completion_date": "2029-04-20", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-11-08T18:52:18.889Z", "location_count": 7, "location_summary": "Chicago, Illinois • Baltimore, Maryland • Chapel Hill, North Carolina + 3 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05029999" }, { "nct_id": "NCT02389764", "title": "Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "BIBF 1120", "type": "DRUG" }, { "name": "Phone Call", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2015-06-22", "completion_date": "2019-06-08", "has_results": true, "last_update_posted_date": "2019-07-17", "last_synced_at": "2026-11-08T18:52:18.889Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02389764" }, { "nct_id": "NCT00651976", "title": "Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "letrozole", "type": "DRUG" }, { "name": "Blood Collection", "type": "OTHER" }, { "name": "biopsy/lumpectomy/mastectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 213, "start_date": "2008-03", "completion_date": "2018-09", "has_results": false, "last_update_posted_date": "2018-10-15", "last_synced_at": "2026-11-08T18:52:18.889Z", "location_count": 5, "location_summary": "Atlanta, Georgia • Tulsa, Oklahoma • Pittsburgh, Pennsylvania + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Tulsa", "state": "Oklahoma" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00651976" } ] }